Apoptosis and colorectal cancer: implications for therapy

Trends in Molecular Medicine

Volumn 15, Issue 5, 2009, Pages 225-233

  Yang, Shi Yu ^a   Sales, Kevin M ^a   Fuller, Barry ^a   Seifalian, Alexander M ^a   Winslet, Marc C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; CASPASE 8; CYCLOOXYGENASE 2; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROSTAGLANDIN E2; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SOMATOMEDIN C; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SIGNAL TRANSDUCTION;

EID: 65549165842     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.03.003     Document Type: Review

References (82)

1. Ferlay J., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18 (2007) 581-592
2. Jemal A., et al. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
3. American Cancer Society. Cancer Facts and Figures 2008 (2008), American Cancer Society
4. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
5. Johnstone R.W., et al. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
6. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17 (1999) 2941-2953
7. Watson A.J., and Pritchard D.M. Lessons from genetically engineered animal models. VII. Apoptosis in intestinal epithelium: lessons from transgenic and knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol 278 (2000) G1-G5
8. Shih I.M., et al. Top-down morphogenesis of colorectal tumors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2640-2645
9. Preston S.L., et al. Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res. 63 (2003) 3819-3825
10. Leedham S.J., and Wright N.A. Expansion of a mutated clone: from stem cell to tumour. J. Clin. Pathol. 61 (2008) 164-171
11. Rajagopalan H., et al. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 3 (2003) 695-701
12. Kim J.M., et al. Apoptosis of human intestinal epithelial cells after bacterial invasion. J. Clin. Invest. 102 (1998) 1815-1823
13. Oumouna-Benachour K., et al. Intrinsic resistance to apoptosis of colon epithelial cells is a potential determining factor in the susceptibility of the A/J mouse strain to dimethylhydrazine-induced colon tumorigenesis. Mol. Carcinog. 46 (2007) 993-1002
14. Kosinski C., et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15418-15423
15. L-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 60 (2000) 3051-3057
16. Bedi A., et al. Inhibition of apoptosis during development of colorectal-cancer. Cancer Res. 55 (1995) 1811-1816
17. Kukitsu T., et al. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Clin. Cancer Res. 14 (2008) 48-54
18. Kikuchi Y., et al. Proliferation and apoptosis in proliferative lesions of the colon and rectum. Virchows Arch. 431 (1997) 111-117
19. Reya T., and Clevers H. Wnt signalling in stem cells and cancer. Nature 434 (2005) 843-850
20. Kim P.J., et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 362 (2003) 205-209
21. Lapham A., et al. The Bcl-w promoter is activated by β-catenin/TCF4 in human colorectal carcinoma cells. Gene 432 (2009) 112-117
22. Youle R.J., and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9 (2008) 47-59
23. Cao J., et al. Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication. Surg. Oncol. 15 (2006) 223-233
24. Coppola D., et al. Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer 113 (2008) 2665-2670
25. Duckworth C.A., and Pritchard D.M. Suppression of apoptosis, crypt hyperplasia, and altered differentiation in the colonic epithelia of bak-null mice. Gastroenterology 136 (2009) 943-952
26. Russo A., et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 23 (2005) 7518-7528
27. Fazeli A., et al. Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10199-10204
28. Greenhough A., et al. The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30 (2009) 377-386
29. Hawk E.T., et al. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog. Exp. Tumor Res. 37 (2003) 210-242
30. Williams C.S., et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000) 6045-6051
31. Sun Y., et al. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 62 (2002) 6323-6328
32. Li W., et al. Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis. Biochem. Pharmacol. 76 (2008) 1485-1489
33. Lagadec P., et al. Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br. J. Cancer 98 (2008) 335-344
34. Luo J.L., et al. Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6 (2004) 297-305
35. Grady W.M. Making the case for DCC and UNC5C as tumor-suppressor genes in the colon. Gastroenterology 133 (2007) 2045-2049
36. Mazelin L., et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 431 (2004) 80-84
37. Shin S.K., et al. Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology 133 (2007) 1849-1857
38. Shi Y., and Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
39. Wang J., et al. Transforming growth factor β induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 68 (2008) 3152-3160
40. Grady W.M., et al. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res. 59 (1999) 320-324
41. Herzer K., et al. Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology 42 (2005) 183-192
42. Wakefield L.M., and Stuelten C. Keeping order in the neighborhood: new roles for TGFβ in maintaining epithelial homeostasis. Cancer Cell 12 (2007) 293-295
43. Mita A.C., et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 14 (2008) 5000-5005
44. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4 (2004) 592-603
45. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 (2003) 8581-8589
46. Prabhudesai S.G., et al. Apoptosis and chemo-resistance in colorectal cancer. J. Surg. Oncol. 96 (2007) 77-88
47. Kawasaki H., et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58 (1998) 5071-5074
48. Oshima T., et al. Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: Insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol. Rep. 20 (2008) 359-364
49. Yang S.Y., et al. Inducing apoptosis of human colon cancer cells by an IGF-I D domain analogue peptide. Mol. Cancer 7 (2008) 17
50. Alami N., et al. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm. IGF Res. 18 (2008) 487-496
51. Durai R., et al. Insulin-like growth factor binding protein-4 gene therapy increases apoptosis by altering Bcl-2 and Bax proteins and decreases angiogenesis in colorectal cancer. Int. J. Oncol. 30 (2007) 883-888
52. Kinoshita K., et al. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol. Cell. Biol. 20 (2000) 4680-4690
53. Beck P.L., et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 126 (2004) 796-808
54. Wei M.C., et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
55. Waterhouse N.J., et al. Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J. Cell Biol. 153 (2001) 319-328
56. Takeda K., et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7 (2001) 94-100
57. Longley D.B., et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res. 62 (2002) 2644-2649
58. Arango D., et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 91 (2004) 1931-1946
59. INK4a loss. Genes Dev. 22 (2008) 1337-1344
60. Spitz F.R., et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 16 (1996) 3415-3422
61. Harris M.P., et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 3 (1996) 121-130
62. min/+ mice. Cancer Res. 68 (2008) 7670-7675
63. Wang W., et al. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11003-11008
64. Bischoff J.R., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
65. Heise C., et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3 (1997) 639-645
66. Reid T.R., et al. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 12 (2005) 673-681
67. Wacheck V., et al. Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells. Br. J. Cancer 89 (2003) 1352-1357
68. L, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin. Cancer Res. 9 (2003) 866-871
69. Subramaniam D., et al. Activation of apoptosis by 1-hydroxy-5,7-dimethoxy-2-naphthalene-carboxaldehyde, a novel compound from Aegle marmelos. Cancer Res. 68 (2008) 8573-8581
70. Rahme E., et al. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125 (2003) 404-412
71. Harris R.E., et al. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 8 (2008) 237
72. Yamamoto T., et al. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur. J. Cancer 38 (2002) 2316-2324
73. Tsuruma T., et al. Phase I trial of survivin2B peptide vaccination therapy for the advanced or reccurrent colorectal cancer. Dis. Colon Rectum 47 (2004) 1099-1100
74. Burtrum D., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63 (2003) 8912-8921
75. Ji Q.S., et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo. Mol. Cancer Ther. 6 (2007) 2158-2167
76. Wang J., et al. Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells. J. Biol. Chem. 271 (1996) 17366-17371
77. Marini P., et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25 (2006) 5145-5154
78. Plummer R., et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13 (2007) 6187-6194
79. Scott N., et al. Genes mediating programmed cell death: an immunohistochemical study of bcl-2, c-myc and p53 expression in colorectal neoplasia. Clin. Mol. Pathol. 49 (1996) M151-M158
80. Berney C.R., et al. Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. J. Pathol. 191 (2000) 15-20
81. Kitamura S., et al. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br. J. Cancer 83 (2000) 668-673
82. Carr N.J., et al. Epithelial neoplasms of the appendix and colorectum - An analysis of cell proliferation, apoptosis, and expression of p53, CD44, and bcl-2. Arch. Pathol. Lab. Med. 126 (2002) 837-841